TissueGene, Inc. Report issue

For profit Phase 2 Phase 3
Founded: Rockville MD United States (1999)

Organization Overview

First Clinical Trial
2007
NCT00599248
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Kolon Life Science | Kolon TissueGene, Inc. | TissueGene, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

allogenic human chondrocytes expressing transforming growth factor-β1 (7 trials)

invossa (1 trial)

tg-c (2 trials)

Drugs in Phase 2 Trials (1)

kls-2031 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Joint Diseases (Phase 2)

Neuralgia (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Radiculopathy (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4